Yang LI et al. - In the current study, the addition of cetuximab to concurrent chemoradiotherapy (CCRT) did not improve benefits in survival in stage II to IV nasopharyngeal carcinoma (NPC).

Methods
62 patients treated with CCRT plus cetuximab were matched with 124 patients treated with CCRT alone.  
OS,PFS, locoregional recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS) were assessed.

Results
Compared to CCRT alone, adding cetuximab resulted in more grade 3-4 radiation mucositis (51.6% vs. 23.4%, respectively).
No differences existed between the CCRT + cetuximab group and the CCRT group in 5-year OS (89.7% vs. 90.7%, respectively), 3-year PFS (83.9% vs. 88.7%, respectively), the 3-year LRFS (95.0% vs. 96.7%, respectively), and the 3-year DMFS (88.4% vs 91.9%, respectively).
Advanced disease stage was the independent prognostic factor that best predicted poorer OS and PFS.